BioSpace News Archive

MorphoSys AG announced Thursday it plans to drop its pre-clinical programs and cut 17% of its workforce in an effort to extend its cash runway.

Eli Lilly is expanding its pain management pipeline with a new asset from Belgium-based Confo Therapeutics targeting the angiotensin II type 2 receptor.

Results from the largest-ever trial of a four-day workweek showed overwhelming success, but is that success possible for biopharma companies?

Novo Nordisk announced Thursday it plans to expand its research and development operations in the greater Boston area and add over 200 new jobs this year.

Thymmune is backed by an A-list team of investors including Pillar VC, former Alnylam CEO John Maraganore and famed geneticist George Church.

Valneva SE, a specialty vaccine company, announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001.

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Karen Massey will join argenx as Chief Operating Officer, effective March 13, 2023.

Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced financial results for the 12-month period from January 1 to December 31, 2022 and provided a corporate update.

The XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of ALTUVIIIO as once-weekly prophylaxis in previously treated patients <12 years of age with severe hemophilia A met its primary endpoint of safety, with no FVIII inhibitors detected in 74 children, with more than 50 children experiencing at least 50 exposure days, nearly a full year of treatment.

Oxurion NV and Negma Group announce that their funding program has ended, pursuant to the terms and conditions of the Issuance and Subscription agreement entered into by the Company with the Negma Group on August 26, 2021, as amended on September 2, 2022 and January 25, 2023.